Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUSPAMARK: Biomarkers of Luspatercept in MDS
NCT07830004Phase 4Not yet recruiting
- Sponsor
- CHU Grenoble Alpes
- Start
- Nov 2026
- Primary completion
- May 2031
01
Overview
A Phase 4 trial of luspatercept in myelodysplastic syndrome (MDS), sponsored by CHU Grenoble Alpes. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07830004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07830004.